{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:24:14Z","timestamp":1784607854022,"version":"3.55.0"},"reference-count":53,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2019.0670","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T08:31:55Z","timestamp":1569486715000},"source":"Crossref","is-referenced-by-count":12,"title":["The Role of Microbiota in Preventing Multidrug-Resistant Bacterial Infections"],"prefix":"10.3238","author":[{"given":"Yascha","family":"Khodamoradi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg Janne","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J. G. T.","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2019,10,4]]},"reference":[{"key":"10.3238\/arztebl.2019.0670_ref1","doi-asserted-by":"crossref","unstructured":"Agusti A, Garcia-Pardo MP, Lopez-Almela I, et al.: Interplay between the gut-brain axis, obesity and cognitive function. Front Neurosci 2018; 12: 155","DOI":"10.3389\/fnins.2018.00155"},{"key":"10.3238\/arztebl.2019.0670_ref2","doi-asserted-by":"crossref","unstructured":"Bibbo S, Ianiro G, Dore MP, Simonelli C, Newton EE, Cammarota G: Gut microbiota as a driver of inflammation in nonalcoholic fatty liver disease. Mediators Inflamm 2018; 2018: 9321643","DOI":"10.1155\/2018\/9321643"},{"key":"10.3238\/arztebl.2019.0670_ref3","doi-asserted-by":"crossref","unstructured":"Tweedle JL, Deepe GS, Jr.: TNFalpha antagonism reveals a gut\/lung axis that amplifies regulatory T cells in a pulmonary fungal infection. Infect Immun 2018; 86: pii: e00109\u201318","DOI":"10.1128\/IAI.00109-18"},{"key":"10.3238\/arztebl.2019.0670_ref4","doi-asserted-by":"crossref","unstructured":"Tamburini S, Shen N, Wu HC, Clemente JC: The microbiome in early life: implications for health outcomes. Nat Med 2016; 22: 713\u201322","DOI":"10.1038\/nm.4142"},{"key":"10.3238\/arztebl.2019.0670_ref5","doi-asserted-by":"crossref","unstructured":"Caballero S, Kim S, Carter RA, et al.: Cooperating commensals restore colonization resistance to vancomycin-resistant enterococcus faecium. Cell Host Microbe 2017; 21: 592\u2013602.","DOI":"10.1016\/j.chom.2017.04.002"},{"key":"10.3238\/arztebl.2019.0670_ref6","doi-asserted-by":"crossref","unstructured":"Haak BW, Prescott HC, Wiersinga WJ: Therapeutic potential of the gut microbiota in the prevention and treatment of sepsis. Front Immunol 2018; 9: 2042","DOI":"10.3389\/fimmu.2018.02042"},{"key":"10.3238\/arztebl.2019.0670_ref7","doi-asserted-by":"crossref","unstructured":"Taur Y, Jenq RR, Perales MA, et al.: The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 2014; 124: 1174\u201382","DOI":"10.1182\/blood-2014-02-554725"},{"key":"10.3238\/arztebl.2019.0670_ref8","doi-asserted-by":"crossref","unstructured":"Karkman A, Lehtimaki J, Ruokolainen L: The ecology of human microbiota: dynamics and diversity in health and disease. Ann N Y Acad Sci 2017; 1399: 78\u201392","DOI":"10.1111\/nyas.13326"},{"key":"10.3238\/arztebl.2019.0670_ref9","doi-asserted-by":"crossref","unstructured":"Milani C, Duranti S, Bottacini F, et al.: The first microbial colonizers of the human gut: composition, activities, and health implications of the infant gut microbiota. Microbiol Mol Biol Rev 2017; 81: pii: e00036\u201317","DOI":"10.1128\/MMBR.00036-17"},{"key":"10.3238\/arztebl.2019.0670_ref10","doi-asserted-by":"crossref","unstructured":"Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E: Dysbiosis and the immune system. Nat Rev Immunol 2017; 17: 219\u201332","DOI":"10.1038\/nri.2017.7"},{"key":"10.3238\/arztebl.2019.0670_ref11","doi-asserted-by":"crossref","unstructured":"Isaac S, Scher JU, Djukovic A, et al.: Short- and long-term effects of oral vancomycin on the human intestinal microbiota. J Antimicrob Chemother 2017; 72: 128\u201336","DOI":"10.1093\/jac\/dkw383"},{"key":"10.3238\/arztebl.2019.0670_ref12","doi-asserted-by":"crossref","unstructured":"Haak BW, Lankelma JM, Hugenholtz F, Belzer C, de Vos WM, Wiersinga WJ: Long-term impact of oral vancomycin, ciprofloxacin and metronidazole on the gut microbiota in healthy humans. J Antimicrob Chemother 2019; 74: 782\u20136","DOI":"10.1093\/jac\/dky471"},{"key":"10.3238\/arztebl.2019.0670_ref13","doi-asserted-by":"crossref","unstructured":"Taur Y, Xavier JB, Lipuma L, et al.: Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012; 55: 905\u201314","DOI":"10.1093\/cid\/cis580"},{"key":"10.3238\/arztebl.2019.0670_ref14","doi-asserted-by":"crossref","unstructured":"Zakharkina T, Martin-Loeches I, Matamoros S, et al.: The dynamics of the pulmonary microbiome during mechanical ventilation in the intensive care unit and the association with occurrence of pneumonia. Thorax 2017; 72: 803\u201310","DOI":"10.1136\/thoraxjnl-2016-209158"},{"key":"10.3238\/arztebl.2019.0670_ref15","doi-asserted-by":"crossref","unstructured":"Kelly BJ, Imai I, Bittinger K, et al.: Composition and dynamics of the respiratory tract microbiome in intubated patients. Microbiome 2016; 4: 7","DOI":"10.1186\/s40168-016-0151-8"},{"key":"10.3238\/arztebl.2019.0670_ref16","doi-asserted-by":"crossref","unstructured":"Rosshart SP, Vassallo BG, Angeletti D, et al.: Wild mouse gut microbiota promotes host fitness and improves disease resistance. Cell 2017; 171: 1015\u201328.","DOI":"10.1016\/j.cell.2017.09.016"},{"key":"10.3238\/arztebl.2019.0670_ref17","doi-asserted-by":"crossref","unstructured":"Thackray LB, Handley SA, Gorman MJ, et al.: Oral antibiotic treatment of mice exacerbates the disease severity of multiple flavivirus infections. Cell Rep 2018; 22: 3440\u201353","DOI":"10.1016\/j.celrep.2018.03.001"},{"key":"10.3238\/arztebl.2019.0670_ref18","doi-asserted-by":"crossref","unstructured":"Haak BW, Littmann ER, Chaubard JL, et al.: Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT. Blood 2018; 131: 2978\u201386 MEDLINE","DOI":"10.1182\/blood-2018-01-828996"},{"key":"10.3238\/arztebl.2019.0670_ref19","doi-asserted-by":"crossref","unstructured":"Davey P, Marwick CA, Scott CL, et al.: Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2017; 2: CD003543","DOI":"10.1002\/14651858.CD003543.pub4"},{"key":"10.3238\/arztebl.2019.0670_ref20","doi-asserted-by":"crossref","unstructured":"Willemsen I, van den Broek R, Bijsterveldt T, et al.: A standardized protocol for perioperative antibiotic prophylaxis is associated with improvement of timing and reduction of costs. J Hosp Infect 2007; 67: 156\u201360","DOI":"10.1016\/j.jhin.2007.07.025"},{"key":"10.3238\/arztebl.2019.0670_ref21","doi-asserted-by":"crossref","unstructured":"Kraus EM, Pelzl S, Szecsenyi J, Laux G: Antibiotic prescribing for acute lower respiratory tract infections (LRTI)\u2014guideline adherence in the German primary care setting: an analysis of routine data. PLoS One 2017; 12: e0174584","DOI":"10.1371\/journal.pone.0174584"},{"key":"10.3238\/arztebl.2019.0670_ref22","doi-asserted-by":"crossref","unstructured":"Plachouras D, Karki T, Hansen S, et al.: Antimicrobial use in European acute care hospitals: results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017. Euro Surveill 2018; 23","DOI":"10.2807\/1560-7917.ES.23.46.1800393"},{"key":"10.3238\/arztebl.2019.0670_ref23","doi-asserted-by":"crossref","unstructured":"de Jong E, van Oers JA, Beishuizen A, et al.: Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 2016; 16: 819\u201327","DOI":"10.1016\/S1473-3099(16)00053-0"},{"key":"10.3238\/arztebl.2019.0670_ref24","doi-asserted-by":"crossref","unstructured":"Baggs J, Jernigan JA, Halpin AL, Epstein L, Hatfield KM, McDonald LC: Risk of subsequent sepsis within 90 days after a hospital stay by type of antibiotic exposure. Clin Infect Dis 2018; 66: 1004\u201312","DOI":"10.1093\/cid\/cix947"},{"key":"10.3238\/arztebl.2019.0670_ref25","doi-asserted-by":"crossref","unstructured":"Barlow G, Patterson J, Stultz J, Pakyz AL: Associations between antimicrobial stewardship program elements and clostridium difficile infection performance. Am J Infect Control 2017; 45: 1399\u2013401","DOI":"10.1016\/j.ajic.2017.06.022"},{"key":"10.3238\/arztebl.2019.0670_ref26","doi-asserted-by":"crossref","unstructured":"Baur D, Gladstone BP, Burkert F, et al.: Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis 2017; 17: 990\u20131001","DOI":"10.1016\/S1473-3099(17)30325-0"},{"key":"10.3238\/arztebl.2019.0670_ref27","doi-asserted-by":"crossref","unstructured":"de Gunzburg J, Ghozlane A, Ducher A, et al.: Protection of the human gut microbiome from antibiotics. J Infect Dis 2018; 217: 628\u201336","DOI":"10.1093\/infdis\/jix604"},{"key":"10.3238\/arztebl.2019.0670_ref28","doi-asserted-by":"crossref","unstructured":"Kokai-Kun JF, Roberts T, Coughlin O, et al.: Use of ribaxamase (SYN-004), a beta-lactamase, to prevent clostridium difficile infection in beta-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial. Lancet Infect Dis; 01919: 487\u201396","DOI":"10.1016\/S1473-3099(18)30731-X"},{"key":"10.3238\/arztebl.2019.0670_ref29","doi-asserted-by":"crossref","unstructured":"Guery B, Menichetti F, Anttila VJ, et al.: Extended-pulsed fidaxomicin versus vancomycin for clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b\/4 trial. Lancet Infect Dis 2018; 18: 296\u2013307","DOI":"10.1016\/S1473-3099(17)30751-X"},{"key":"10.3238\/arztebl.2019.0670_ref30","doi-asserted-by":"crossref","unstructured":"Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ: Reduced acquisition and overgrowth of vancomycin-resistant enterococci and candida species in patients treated with fidaxomicin versus vancomycin for clostridium difficile infection. Clin Infect Dis 2012; 55 (Suppl 2): S121\u20136","DOI":"10.1093\/cid\/cis440"},{"key":"10.3238\/arztebl.2019.0670_ref31","doi-asserted-by":"crossref","unstructured":"Lin DM, Koskella B, Lin HC: Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther 2017; 8: 162\u201373","DOI":"10.4292\/wjgpt.v8.i3.162"},{"key":"10.3238\/arztebl.2019.0670_ref32","doi-asserted-by":"crossref","unstructured":"Jouhten H, Mattila E, Arkkila P, Satokari R: Reduction of antibiotic resistance genes in intestinal microbiota of patients with recurrent clostridium difficile infection after fecal microbiota transplantation. Clin Infect Dis 2016; 63: 710\u20131","DOI":"10.1093\/cid\/ciw390"},{"key":"10.3238\/arztebl.2019.0670_ref33","doi-asserted-by":"crossref","unstructured":"Leung V, Vincent C, Edens TJ, Miller M, Manges AR: Antimicrobial resistance gene acquisition and depletion following fecal microbiota transplantation for recurrent clostridium difficile infection. Clin Infect Dis 2018; 66: 456\u20137","DOI":"10.1093\/cid\/cix821"},{"key":"10.3238\/arztebl.2019.0670_ref34","doi-asserted-by":"crossref","unstructured":"Dubberke ER, Mullane KM, Gerding DN, et al.: Clearance of vancomycin-resistant enterococcus concomitant with administration of a microbiota-based drug targeted at recurrent clostridium difficile infection. Open Forum Infect Dis 2016; 3: ofw133","DOI":"10.1093\/ofid\/ofw133"},{"key":"10.3238\/arztebl.2019.0670_ref35","doi-asserted-by":"crossref","unstructured":"Elison E, Vigsnaes LK, Rindom Krogsgaard L, et al.: Oral supplementation of healthy adults with 2\u2018-O-fucosyllactose and lacto-N-neotetraose is well tolerated and shifts the intestinal microbiota. Br J Nutr 2016; 116: 1356\u201368","DOI":"10.1017\/S0007114516003354"},{"key":"10.3238\/arztebl.2019.0670_ref36","doi-asserted-by":"crossref","unstructured":"Manley KJ, Fraenkel MB, Mayall BC, Power DA: Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust 2007; 186: 454\u20137","DOI":"10.5694\/j.1326-5377.2007.tb00995.x"},{"key":"10.3238\/arztebl.2019.0670_ref37","doi-asserted-by":"crossref","unstructured":"Szachta P, Ignys I, Cichy W: An evaluation of the ability of the probiotic strain lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant enterococci in colonized children. J Clin Gastroenterol 2011; 45: 872\u20137","DOI":"10.1097\/MCG.0b013e318227439f"},{"key":"10.3238\/arztebl.2019.0670_ref38","doi-asserted-by":"crossref","unstructured":"Salomao MC, Heluany-Filho MA, Menegueti MG, Kraker ME, Martinez R, Bellissimo-Rodrigues F: A randomized clinical trial on the effectiveness of a symbiotic product to decolonize patients harboring multidrug-resistant gram-negative bacilli. Rev Soc Bras Med Trop 2016; 49: 559\u201366","DOI":"10.1590\/0037-8682-0233-2016"},{"key":"10.3238\/arztebl.2019.0670_ref39","doi-asserted-by":"crossref","unstructured":"Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A: bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 2009; 18: 237\u20138, 240\u20133","DOI":"10.12968\/jowc.2009.18.6.42801"},{"key":"10.3238\/arztebl.2019.0670_ref40","doi-asserted-by":"crossref","unstructured":"Wright A, Hawkins CH, Anggard EE, Harper DR: A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009; 34: 349\u201357","DOI":"10.1111\/j.1749-4486.2009.01973.x"},{"key":"10.3238\/arztebl.2019.0670_ref41","unstructured":"Rose T, Verbeken G, Vos DD, et al.: Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma 2014; 4: 66\u201373."},{"key":"10.3238\/arztebl.2019.0670_ref42","doi-asserted-by":"crossref","unstructured":"Sarker SA, Sultana S, Reuteler G, et al.: Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 2016; 4: 124\u201337 MEDLINE","DOI":"10.1016\/j.ebiom.2015.12.023"},{"key":"10.3238\/arztebl.2019.0670_ref43","doi-asserted-by":"crossref","unstructured":"Ooi ML, Drilling AJ, Morales S, et al.: Safety and tolerability of bacteriophage therapy for chronic rhinosinusitis due to staphylococcus aureus. JAMA Otolaryngol Head Neck Surg 2019. doi: 10.1001\/jamaoto.2019.1191 (Epub ahead of print)","DOI":"10.1001\/jamaoto.2019.1191"},{"key":"10.3238\/arztebl.2019.0670_ref44","doi-asserted-by":"crossref","unstructured":"Singh R, van Nood E, Nieuwdorp M, et al.: Donor feces infusion for eradication of extended spectrum beta-lactamase producing Escherichia coli in a patient with end stage renal disease. Clin Microbiol Infect 2014; 20: O977\u20138","DOI":"10.1111\/1469-0691.12683"},{"key":"10.3238\/arztebl.2019.0670_ref45","doi-asserted-by":"crossref","unstructured":"Lagier JC, Million M, Fournier PE, Brouqui P, Raoult D: Faecal microbiota transplantation for stool decolonization of OXA-48 carbapenemase-producing klebsiella pneumoniae. J Hosp Infect 2015; 90: 173\u20134","DOI":"10.1016\/j.jhin.2015.02.013"},{"key":"10.3238\/arztebl.2019.0670_ref46","doi-asserted-by":"crossref","unstructured":"Davido B, Batista R, Michelon H, et al.: Is faecal microbiota transplantation an option to eradicate highly drug-resistant enteric bacteria carriage? J Hosp Infect 2017; 95: 433\u20137","DOI":"10.1016\/j.jhin.2017.02.001"},{"key":"10.3238\/arztebl.2019.0670_ref47","doi-asserted-by":"crossref","unstructured":"Bilinski J, Grzesiowski P, Sorensen N, et al.: Fecal microbiota transplantation in patients with blood disorders inhibits gut colonization with antibiotic-resistant bacteria: results of a prospective, single-center study. Clin Infect Dis 2017; 65: 364\u201370","DOI":"10.1093\/cid\/cix252"},{"key":"10.3238\/arztebl.2019.0670_ref48","doi-asserted-by":"crossref","unstructured":"Stalenhoef JE, Terveer EM, Knetsch CW, et al.: Fecal microbiota transfer for multidrug-resistant gram-negatives: a clinical success combined with microbiological failure. Open Forum Infect Dis 2017; 4: ofx047","DOI":"10.1093\/ofid\/ofx047"},{"key":"10.3238\/arztebl.2019.0670_ref49","doi-asserted-by":"crossref","unstructured":"Lahtinen P, Mattila E, Anttila VJ, et al.: Faecal microbiota transplantation in patients with clostridium difficile and significant comorbidities as well as in patients with new indications: a case series. World J Gastroenterol 2017; 23: 7174\u201384","DOI":"10.3748\/wjg.v23.i39.7174"},{"key":"10.3238\/arztebl.2019.0670_ref50","doi-asserted-by":"crossref","unstructured":"Singh R, de Groot PF, Geerlings SE, et al.: Fecal microbiota transplantation against intestinal colonization by extended spectrum beta-lactamase producing enterobacteriaceae: a proof of principle study. BMC Res Notes 2018; 11: 190","DOI":"10.1186\/s13104-018-3293-x"},{"key":"10.3238\/arztebl.2019.0670_ref51","doi-asserted-by":"crossref","unstructured":"Dinh A, Fessi H, Duran C, et al.: Clearance of carbapenem-resistant enterobacteriaceae vs vancomycin-resistant enterococci carriage after faecal microbiota transplant: a prospective comparative study. J Hosp Infect 2018; 99: 481\u20136","DOI":"10.1016\/j.jhin.2018.02.018"},{"key":"10.3238\/arztebl.2019.0670_ref52","doi-asserted-by":"crossref","unstructured":"Sa\u00efdani N, Lagier JC, Cassir N, et al.: Faecal microbiota transplantation shortens the colonisation period and allows re-entry of patients carrying carbapenamase-producing bacteria into medical care facilities. Int J Antimicrob Agents 2019; 53: 355\u201361","DOI":"10.1016\/j.ijantimicag.2018.11.014"},{"key":"10.3238\/arztebl.2019.0670_ref53","doi-asserted-by":"crossref","unstructured":"Huttner BD, de Lastours V, Wassenberg M, et al.: A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial. Clin Microbiol Infect 2019; 25: 830\u20138","DOI":"10.1016\/j.cmi.2019.02.001"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2019.0670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T10:26:32Z","timestamp":1638786392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2019.0670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,4]]},"references-count":53,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2019.0670","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,4]]}}}